Adocia announced the creation of a subsidiary in the USA, Adocia Incorporated. Opening a US subsidiary is a key step in Adocia's strategy, the USA are currently the primary market for its products. Adocia has developed BioChaperone® pipeline products in order to improve the insulin based treatments for diabetes, monoclonal antibodies and growth factors for the diabetic foot ulcer healing. Last December 2014, Adocia announced an alliance with Eli Lilly to co-develop BioChaperone Lispro, which is one of its products for the treatment of diabetes.

The company announced the accompanying appointments of Simon Bruce, MD and Stephen Daly. Two employees are already appointed, Simon Bruce, M.D., Chief Medical Officer and Stephen Daly, US Commercial Lead who is in charge of the business development in the USA and also of the US investors relations. Dr. Bruce, who originally trained in endocrine clinical research at the National Institutes of Health in Bethesda, MD, has over 15 years of experience drug development and registrational drug trials. In his last job at Halozyme Pharmaceuticals, Dr. Bruce held a position as an Executive Medical Director working on the ultra-rapid insulin program. Stephen Daly has 24 years of experience in commercialization and business development for pharmaceutical and biotech products across multiple therapeutic categories. Most recently, he served as the Vice President of Commercial at Halozyme Therapeutics for their ultra-rapid insulin program.